首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal CDC25B Antibody

  • 中文名: CDC25B 抗体
  • 别    名: nan
货号: IPDX04351
Price: ¥1180
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 1/50-1/200 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/2000-1/5000 Human,Mouse,Rat

产品详情

Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenSynthetic peptide of human CDC25B
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

参考文献

以下是关于CDC25B抗体的3篇参考文献示例(文献信息及摘要内容为虚构示例,仅供格式参考):

1. **文献名称**:*CDC25B phosphatase is a prognostic marker in ovarian cancer and regulates cell cycle progression*

**作者**:Kristjansdottir K, et al.

**摘要**:本研究通过免疫组化(使用CDC25B特异性抗体)发现CDC25B在卵巢癌组织中过表达,并与患者生存率降低相关。实验表明,CDC25B通过调控G2/M期转换促进肿瘤细胞增殖。

2. **文献名称**:*Phosphorylation-dependent regulation of CDC25B subcellular localization*

**作者**:Boutros R, et al.

**摘要**:利用CDC25B抗体进行Western blot和免疫荧光实验,揭示CDC25B的磷酸化状态影响其核质转运,从而调控细胞周期检查点应答,为靶向CDC25B的癌症治疗提供理论依据。

3. **文献名称**:*CDC25B expression correlates with aggressive phenotypes in breast cancer*

**作者**:Cheng L, et al.

**摘要**:通过组织芯片和CDC25B抗体检测,发现CDC25B在三阴性乳腺癌中高表达,且与转移风险增加相关。体外实验证实抑制CDC25B可降低癌细胞侵袭能力。

---

如需真实文献,建议通过PubMed或Google Scholar检索关键词“CDC25B antibody”或“CDC25B cancer”,筛选近5-10年高引用论文。

背景信息

The CDC25B antibody is a critical tool for studying the CDC25B phosphatase, a member of the CDC25 family (CDC25A, B, C) that regulates cell cycle progression by activating cyclin-dependent kinases (CDKs). CDC25B specifically dephosphorylates CDK1 at inhibitory residues, driving the transition from G2 to M phase. Its dysregulation is linked to cancer, as overexpression can disrupt cell cycle checkpoints, promoting genomic instability and tumorigenesis. The antibody enables detection and quantification of CDC25B protein in various applications, including Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding research on its expression patterns in normal tissues and malignancies. Studies using CDC25B antibodies have revealed its prognostic value in cancers like breast, lung, and colorectal, where elevated levels correlate with poor outcomes. Additionally, these antibodies are instrumental in exploring CDC25B's role in drug resistance and as a therapeutic target. Commercially available CDC25B antibodies are typically raised against specific epitopes, with validation via knockout controls or peptide blocking to ensure specificity. Researchers prioritize antibodies with high sensitivity and minimal cross-reactivity to other CDC25 isoforms. As CDC25B inhibitors emerge in preclinical studies, reliable antibodies remain essential for mechanistic insights and translational applications in oncology and cell cycle biology.

客户数据及评论

折叠内容

大包装询价

×